Greg Motz

Greg Motz

Company: Unum Therapeutics

Job title: Director, Immunopharmacology


ACTR and BOXR: Addressing the Challenges of T-Cell Therapies in Solid Tumors 4:55 pm

Key challenges facing T-cell therapy in solid tumors include on-target/off tumor toxicity and immunosuppression in the tumor microenvironment. Unum has developed two novel T cell technologies to address these challenges The ACTR T-cell platform allows for selective tumor antigen targeting efficiently killing tumor cells with high antigen expression while sparing normal tissues with low antigen…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.